rexlemestrocel-L Updated Jul 3
Mesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure, the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.
- BLA for LVAD/heart failure just filed with FDA (June 30, 2026), and RMAT designation enables accelerated/priority review, a potentially faster path to market
- DREAM-HF Phase 3 data showed up to 60% reduction in cardiovascular death in heart failure patients with inflammation (published in JACC, peer-reviewed)
- CLBP Phase 3 enrollment completed April 2026, addresses a $10B+ market with 7M+ US patients as a non-opioid treatment; FDA has confirmed 12-month pain reduction as an approvable endpoint
- DREAM-HF Phase 3 trial failed its primary endpoint (heart failure hospitalizations); only showed mortality benefit in subgroups, this weakens the clinical package
- LVAD BLA uses a modular review process, which is non-standard and carries timeline uncertainty, no PDUFA date set
- Manufacturing and CMC (chemistry, manufacturing, controls) complexity for cell therapies is a common source of FDA delays and CRLs